Navigation Links
New technique uses 'simulated' human heart to screen drugs
Date:7/21/2014

A Coventry University scientist has developed a pioneering new way using samples of beating heart tissue to test the effect of drugs on the heart without using human or animal trials.

The breakthrough is the work of Dr Helen Maddock an expert in cardiovascular physiology and pharmacology from the University's Centre for Applied Biological and Exercise Sciences and could lead to the lives of hundreds of future patients being saved and the quality of their treatments improved.

Adverse effects of drugs on the cardiovascular system are a major cause of many medical treatments failing, but heart-related side-effects can often only be detected once a drug is being used on patients in clinical trials by which time it is too late.

Dr Maddock's 'in vitro' technique which means 'in glass' in reference to it taking place in a laboratory environment rather than in a living organism uses a specimen of human heart tissue attached to a rig allowing the muscle to be lengthened and shortened whilst being stimulated by an electrical impulse, mimicking the biomechanical performance of cardiac muscle.

Trial drugs can then be added to the tissue to determine whether or not they have an adverse effect on the force of contraction of the muscle (and therefore of the heart), a test that could only previously be performed 'in vivo' i.e. on living animals often with inconclusive results.

This 'simulated' cardiovascular system known as a work-loop assay provides the most realistic model of heart muscle dynamics in the world to date, and opens up unprecedented possibilities for identifying negative effects of drugs early and inexpensively potentially saving lives and speeding up the development of successful drug treatments.

Dr Maddock has formed a spin-out company InoCardia Ltd from Coventry University to begin implementing her groundbreaking technique in the pharma industry, and it has already received a quarter of a million pound investment from Warwickshire-based technology investment firm Mercia Fund Management.

Dr Maddock, who spent almost ten years developing the technique, said:

"I'm delighted that our research is at a stage where we can confidently say the work-loop assay we've created is the world's only clinically relevant in vitro human model of cardiac contractility. It has the potential to shave years off the development of successful drugs for a range of treatments.

"Both the pharma industry and regulators recognise that existing methods of assessing the contractility of the heart are fraught with problems, so we're incredibly excited to be able to introduce a new way to accurately determine the safety of drugs in respect of the heart without the need to test on humans or animals."

Mark Payton, managing director of Mercia Fund Management, added:

"InoCardia benefits from a proprietary approach following many years of investigation by Helen and her team, and offers the potential for early screening of compounds in development without the initial need for extensive animal trials. Through a markedly accelerated drug development process, this will decrease timelines to drug development, and as a consequence greatly reduce the cost of new drug development. The end beneficiary will, of course, be patients receiving novel treatments sooner."

Dr Maddock and InoCardia Ltd are already in discussions with a multinational biopharmaceutical company with a view to applying the assay in industry.


'/>"/>

Contact: Alex Roache
alex.roache@coventry.ac.uk
44-024-776-55050
Coventry University
Source:Eurekalert  

Related biology news :

1. New technique maps lifes effects on our DNA
2. Innovative technique may transform the hunt for new antibiotics and cancer therapies
3. Grass-in-the-ear technique sets new trend in chimp etiquette
4. Research team pursues techniques to improve elusive stem cell therapy
5. Big data technique improves monitoring of kidney transplant patients
6. New digital fabrication technique creates interlocking 3D-printed ceramic PolyBricks
7. Criminal profiling technique targets killer diseases
8. Developing an improved liposuction technique that melts fat
9. New technique to prevent anal sphincter lesions due to episiotomy during child delivery
10. Novel ORNL technique enables air-stable water droplet networks
11. Study validates air sampling techniques to fight bioterrorism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New technique uses 'simulated' human heart to screen drugs
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
(Date:5/16/2017)... --  Bridge Patient Portal , an enterprise patient ... Systems , an electronic medical record solutions developer ... a partnership to build an interface between the ... products, including Centricity Practice Solution (CPS), Centricity Business ... integrations will allow healthcare delivery networks using GE ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert ... a media edge server, the M820, which features the company,s hybrid ... software provided by Tera Probe, Inc., will be showcased during the ... the NAB show at the Las Vegas ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., ... a Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. ... best practices and how Proscia improves lab economics and realizes an increase in ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh ... orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of ... SBT-100 is able to cross the cell membrane and bind intracellular STAT3 and ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
Breaking Biology Technology: